Catherine Owen Adams, Acadia Pharmaceuticals CEO
November 6, 2024 07:04 AM EST
Pharma
FDA+

Aca­dia lands $150M sale of rare pe­di­atric PRV

Katherine Lewin

News Reporter

Aca­dia Phar­ma­ceu­ti­cals has sold its pri­or­i­ty re­view vouch­er for $150 mil­lion, the com­pa­ny said Tues­day, but did not dis­close the buy­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

No­vo un­veils new car­diometa­bol­ic da­ta as it re­ports sol­id third-quar­ter prof­its

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times